AU3755900A - Use of recombinant gene delivery vectors for treating or preventing diseases of the eye - Google Patents

Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Info

Publication number
AU3755900A
AU3755900A AU37559/00A AU3755900A AU3755900A AU 3755900 A AU3755900 A AU 3755900A AU 37559/00 A AU37559/00 A AU 37559/00A AU 3755900 A AU3755900 A AU 3755900A AU 3755900 A AU3755900 A AU 3755900A
Authority
AU
Australia
Prior art keywords
eye
treating
gene delivery
recombinant gene
preventing diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37559/00A
Inventor
Adriana Di Polo
Varavani J. Dwarki
John G. Flannery
Dana Lau
William C. Manning
Laura H. Mcgee
Sheldon Miller
Katherine Rendahl
Fei Wang
Shang-Zhen Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
University of California
Original Assignee
University of California
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Chiron Corp filed Critical University of California
Publication of AU3755900A publication Critical patent/AU3755900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
AU37559/00A 1999-03-15 2000-03-15 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye Abandoned AU3755900A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12446099P 1999-03-15 1999-03-15
US60124460 1999-03-15
US17498400P 2000-01-06 2000-01-06
US60174984 2000-01-06
PCT/US2000/007062 WO2000054813A2 (en) 1999-03-15 2000-03-15 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Publications (1)

Publication Number Publication Date
AU3755900A true AU3755900A (en) 2000-10-04

Family

ID=26822618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37559/00A Abandoned AU3755900A (en) 1999-03-15 2000-03-15 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Country Status (5)

Country Link
EP (1) EP1183051A2 (en)
JP (1) JP2002539176A (en)
AU (1) AU3755900A (en)
CA (1) CA2367375A1 (en)
WO (1) WO2000054813A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008201780B2 (en) * 1999-09-07 2012-05-17 Amgen Inc. Fibroblast growth factor-like polypeptides

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
JP2002542805A (en) 1999-04-30 2002-12-17 ユニバーシティ オブ フロリダ Adeno-associated virus delivery ribozyme compositions and methods of use
US7056885B1 (en) * 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU1101901A (en) * 1999-10-22 2001-05-08 Chiron Corporation Human fgf-20 gene and gene expression products
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
PT1232264E (en) * 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Human fgf-21 gene and gene expression products
EP1253948A2 (en) * 2000-02-11 2002-11-06 Genvec, Inc. Gene therapy for treating ocular-related disorders
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20020037557A1 (en) 2000-03-13 2002-03-28 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
EP1297012A2 (en) * 2000-07-03 2003-04-02 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same
WO2002024234A2 (en) * 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
JP2004537267A (en) * 2000-11-06 2004-12-16 キュラジェン コーポレイション Treatment of inflammatory bowel disease using growth factors
RU2288742C2 (en) * 2000-12-19 2006-12-10 Рисерч Дивелопмент Фаундейшн Gene transition mediated by lentiviral vector and method for using the genes
JP2005500035A (en) * 2001-06-15 2005-01-06 キュラジェン コーポレイション Novel fibroblast growth factor and nucleic acid encoding it
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
WO2003080648A2 (en) * 2002-03-20 2003-10-02 University Of Florida Research Foundation, Inc. Raav vector compositions and methods for the treatment of choroidal neovascularization
ATE405295T1 (en) 2002-05-01 2008-09-15 Univ Florida IMPROVED RAAV EXPRESSION SYSTEMS FOR GENETIC MODIFICATION OF SPECIFIC CAPSID PROTEINS
JP2005218780A (en) * 2004-02-09 2005-08-18 Menicon Co Ltd Manufacturing method of drug time-releasable hydrogel material, by which drug releasing speed can be controlled
PL1804835T3 (en) 2004-09-13 2010-11-30 Genzyme Corp Multimeric constructs
JP5576659B2 (en) * 2006-12-05 2014-08-20 ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング／ マギル ユニバーシティ Methods of using TRK receptor modulators
CA2713755A1 (en) * 2008-02-07 2009-08-13 Ceregene, Inc. Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein
EP2315833B8 (en) 2008-05-20 2015-05-27 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
CN107188950B (en) 2009-05-05 2021-09-28 安姆根有限公司 FGF21 mutant and application thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
CN101947309B (en) * 2010-04-12 2012-09-19 南海朗肽制药有限公司 Human basic fibroblast growth factor eye drops and preparation method thereof
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
EP2601214B1 (en) 2010-08-06 2017-11-01 Genzyme Corporation Vegf antagonist compositions and uses thereof
TWI775096B (en) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
CA3234028A1 (en) 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use
CA2942776C (en) 2014-03-17 2023-01-24 Adverum Biotechnologies, Inc. Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
KR20170137730A (en) 2015-03-02 2017-12-13 애드베룸 바이오테크놀로지스, 인코포레이티드 Composition and method for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2718150B1 (en) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
JP2001501471A (en) * 1996-09-24 2001-02-06 メルク エンド カンパニー インコーポレーテッド Gene therapy for inhibiting angiogenesis
AU7383298A (en) * 1997-05-13 1998-12-08 Regents Of The University Of California, The Novel antiangiogenic peptide agents and their therapeutic and diagnostic use
JPH11100327A (en) * 1997-09-26 1999-04-13 Toray Ind Inc Therapeutic agent for retinal degeneration
EP1019515A1 (en) * 1997-10-01 2000-07-19 G.D. SEARLE & CO. Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment
CA2322380C (en) * 1998-03-12 2008-10-14 Genentech, Inc. Method of preventing the death of retinal neurons and treating ocular diseases
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
AU775245B2 (en) * 1998-09-17 2004-07-22 Catholic University Nijmegen Methods for treatment of degenerative retinal diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008201780B2 (en) * 1999-09-07 2012-05-17 Amgen Inc. Fibroblast growth factor-like polypeptides

Also Published As

Publication number Publication date
WO2000054813A3 (en) 2001-05-03
CA2367375A1 (en) 2000-09-21
WO2000054813A2 (en) 2000-09-21
EP1183051A2 (en) 2002-03-06
JP2002539176A (en) 2002-11-19

Similar Documents

Publication Publication Date Title
AU3755900A (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2001292881A1 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU3347000A (en) Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
IL152549A0 (en) Vectors for ocular transduction and use thereof for genetic therapy
AU2484399A (en) Controlled release delivery of peptide or protein
AU5393400A (en) Device for treating glaucoma of the eye
AU2002322719A1 (en) Delivery of therapeutic capable agents
AU4819300A (en) Methods of refractive correction of the eye
AU2003234529A1 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
AU2853700A (en) Sustained delivery of polyionic bioactive agents
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2002307430A1 (en) Method and system for photodisruption of tissue of the eye
AU6205700A (en) Azo amino acid derivatives for the treatment of neurological diseases
ZA200201819B (en) Preventive and therapeutic agents for eye diseases.
AU4652100A (en) Controlled delivery of bisphosphonates
AU2637100A (en) Delivery system and methods for gene therapy
AU2002325683A1 (en) Recombinant vector derived from adeno-associated virus for gene therapy
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU7077898A (en) Recombinant vectors derived from adeno-associated virus suitable for gene therapy
EP1343532A4 (en) Lentiviral vector-mediated gene transfer and uses thereof
AU2003273983A8 (en) Viral vectors and the use of the same for gene therapy
AU5295500A (en) Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
AUPQ233799A0 (en) Recombinant sub-unit vaccine
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU1027501A (en) Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase